Key Points – Certara reported Q1 2026 revenue of $106.9 million, up 1% year over year, with stronger software sales offsetting weaker services.
Adjusted diluted EPS came in at $0.09, down from $0.14 a year ago. – The company completed the divestiture of its regulatory and medical writing business to Veristat and is reorganizing around two priorities: MID3 and ACE
Management said the reset is meant to sharpen focus, improve predictability, and align the business more closely with its core technology strengths. – Certara is leaning into AI and strategic partnerships, including collaboration with NVIDIA and a new relationship with Altasciences, as it builds an AI-integrated platform. The company also updated full-year 2026 guidance to $395 million to $405 million in revenue and an adjusted EBITDA margin of 30% to 32%. – 3 Momentum Stocks That Could Soar Post-Market Volatility Certara (NASDAQ:CERT) reported first-quarter 2026 revenue of $106.9 million, up 1% from the prior-year period, as stronger software performance offset softer services results and the company outlined a strategic reset under Chief Executive Officer Jon Resnick. Resnick, who said he has passed the 100-day mark as CEO, told investors that the quarter was “in line with our expectations” but “does not reflect the company’s potential.” He said Certara is focused on driving “long-term durable growth” by reshaping its business and portfolio strategy and adding more operational rigor. – Simulations Plus Stock Drops 15% Despite EPS Beat Chief Financial Officer John Gallagher said software revenue rose 7% year over year to $49.7 million, driven by Simcyp, Phoenix and Chemaxon.
Services revenue fell 4% to $57.2 million, reflecting mixed results in model-informed drug development services and softness in regulatory services. Software Bookings Improve, Services Bookings Decline Total bookings for the quarter were $115.3 million, down 2% from a year earlier, while trailing 12-month bookings rose 5% to $479.2…